Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-2 Phase 3 study of KarXT + KarX-EC for agitation associated with Alzheimer's disease
2025-520612-34-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing KarXT + KarX-EC with Matching placebo (2 arms). Primary endpoint: Change from baseline to end of treatment in CMAI-IPA total score. Planned start Nov 2025; status: authorised.
02
Drugs
xanomelineKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-520612-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520612-34-00.